The New England Journal of Medicine on Monday published the results of a Penn Medicine and Children’s Hospital of Philadelphia team’s first efforts to use genetically modified versions of patients’ own T cells to treat pediatric patients with acute lymphoblastic leukemia. The therapy produced complete remissions in the first two children treated, and the first one, 7-year-old Emily Whitehead, remains in remission nearly a year after her treatment. Michael Kalos, PhD, an adjunct associate professor in the department of Pathology and Laboratory Medicine and director of the Translational and Correlative Studies Laboratory at Penn, is quoted in a FOX29 segment and an Agence France-Presse article about the new study results. The study’s co-first author is Stephan A. Grupp, MD, PhD, of The Children’s Hospital of Philadelphia, and Penn’s Carl June, MD, is the senior author. A Philadelphia Inquirer article examining the progress of the T cell therapy research in both adults and children also quotes David Porter, MD, a professor of Medicine and director of Blood and Marrow Transplantation in the Abramson Cancer Center, discussing the team’s plans to collaborate with researchers at the Memorial Sloan-Kettering Cancer Center to study two different versions of modified T cell therapies.